RCA
IBB icon

Runnymede Capital Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Runnymede Capital Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,610
Closed -$206K – 149
2025
Q1 		$206K Sell
1,610
-152
-9% -$20.6K 0.2% 67
2024
Q4 		$233K Buy
+1,762
New +$248K 0.2% 66

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
CB
Commerce Bank Kansas City, Missouri $20.7B AUM 23.76% 1-Year Est. Return

Runnymede Capital Advisors's IBB Position: Q2 2025 in Review

Runnymede Capital Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2025, closing a stake of 1,610 shares — an estimated $206K sold.

Runnymede Capital Advisors first reported a position in IBB in Q4 2024 and held it in 2 quarters. The position peaked at $233K in Q4 2024. 797 funds tracked by Wall St. Rank hold IBB as of Q2 2025.

  • Runnymede Capital Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2025 after selling out during the quarter.
  • Runnymede Capital Advisors sold 1,610 iShares Biotechnology ETF shares in Q2 2025, an estimated $206K.
  • Runnymede Capital Advisors first reported a position in iShares Biotechnology ETF in Q4 2024 and held it in 2 quarters.
  • Runnymede Capital Advisors's iShares Biotechnology ETF position peaked at $233K in Q4 2024.
  • 797 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2025.

Based on Runnymede Capital Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.